OKYO Pharma Limited
NASDAQ: OKYO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert J. Dempsey
- Employees
- 3
- Headquarters
- London, United Kingdom
- IPO year
- 2022
- Market cap
- $59.5M
- Website
- https://www.okyopharma.com
Loading OKYO…
Loading profile data…Frequently asked questions about OKYO
What does OKYO Pharma Limited (OKYO) do?
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the co...
Where does OKYO trade?
OKYO Pharma Limited (OKYO) trades on the NASDAQ Capital Market.
What sector is OKYO in?
OKYO Pharma Limited (OKYO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of OKYO Pharma Limited?
Robert J. Dempsey is the chief executive officer of OKYO Pharma Limited (OKYO).
Where is OKYO Pharma Limited headquartered?
OKYO Pharma Limited is headquartered in United Kingdom.
Does OKYO pay a dividend?
OKYO Pharma Limited (OKYO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OKYO go public?
OKYO Pharma Limited (OKYO) completed its initial public offering in 2022.